Sanofi acquires Vicebio to boost its respiratory vaccine portfolio

Sanofi announces the acquisition of London-based biotechnology company Vicebio Ltd. This agreement strengthens its vaccine portfolio with a vaccine candidate against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Vicebio's Molecular Clamp technology facilitates the development of standard-preservation combination vaccines.

The acquisition includes promising development-stage vaccines, including VXB-241 and VXB-251, targeting several respiratory viruses. Sanofi expects an initial payment of $1.15 billion, with an additional $450 million possible depending on progress. Closing is expected by the end of 2025, subject to regulatory conditions.